4536
SANTEN PHARMACEUTICAL CO.,LTD.
参天製薬
- Industry
- Pharmaceutical
- Market
- Prime
- Accounting standards
- IFRS
- Consolidation basis
- Consolidated
Key metrics
Revenue(million JPY)
Mar 2021
249,605
Mar 2022
266,257
Mar 2023
279,037
Mar 2024
301,965
Mar 2025
300,004
Operating profit(million JPY)
Mar 2021
12,917
Mar 2022
35,886
Mar 2023
-3,090
Mar 2024
38,541
Mar 2025
46,880
Operating profit margin(%)
Mar 2021
5.17
Mar 2022
13.48
Mar 2023
-1.11
Mar 2024
12.76
Mar 2025
15.63
Profit before tax(million JPY)
Mar 2021
12,418
Mar 2022
35,616
Mar 2023
-5,799
Mar 2024
29,874
Mar 2025
47,481
Profit(million JPY)
Mar 2021
6,830
Mar 2022
27,218
Mar 2023
-14,948
Mar 2024
26,642
Mar 2025
36,256
Total assets(million JPY)
Mar 2021
402,353
Mar 2022
459,976
Mar 2023
421,179
Mar 2024
435,699
Mar 2025
409,277
Cash and cash equivalents(million JPY)
Mar 2021
62,888
Mar 2022
83,014
Mar 2023
57,903
Mar 2024
94,582
Mar 2025
92,997
Cash flows from operating activities(million JPY)
Mar 2021
38,808
Mar 2022
46,043
Mar 2023
37,147
Mar 2024
72,649
Mar 2025
60,928
Cash flows from investing activities(million JPY)
Mar 2021
-53,355
Mar 2022
-35,169
Mar 2023
-26,777
Mar 2024
-6,145
Mar 2025
-8,223
Cash flows from financing activities(million JPY)
Mar 2021
-16,685
Mar 2022
5,557
Mar 2023
-37,220
Mar 2024
-34,031
Mar 2025
-53,307
Return on equity(%)
Mar 2021
2.2
Mar 2022
8.4
Mar 2023
-4.7
Mar 2024
8.9
Mar 2025
12.2
Equity ratio(%)
Mar 2021
76.4
Mar 2022
73.4
Mar 2023
69.8
Mar 2024
70.2
Mar 2025
69.9
Earnings per share(JPY per share)
Mar 2021
17.09
Mar 2022
68.07
Mar 2023
-38.6
Mar 2024
72.59
Mar 2025
103.98
Net assets per share(JPY per share)
Mar 2021
769.67
Mar 2022
843.6
Mar 2023
783.3
Mar 2024
843.24
Mar 2025
839.2
Dividend per share(JPY per share)
Mar 2021
28
Mar 2022
32
Mar 2023
32
Mar 2024
33
Mar 2025
36
Payout ratio(%)
Mar 2021
163.84
Mar 2022
47.01
Mar 2023
-
Mar 2024
45.46
Mar 2025
34.62
Disclaimer
The financial information and metrics on this page are based on publicly available filings and other public sources. We do not guarantee their accuracy, completeness, or timeliness.
The information on this page is provided for reference purposes only and does not constitute a recommendation to buy or sell any security. Investment decisions should be made at your own responsibility.